Abstract
Recent advances in designing peptide ligands for therapeutic targets are making peptides an attractive alternative to small molecules and proteins. It is now common to see peptides developed with affinities comparable to antibodies and specificities much better than small molecules or antibodies. This is especially true in the case of tumor targeting cytotoxic drugs or targeted diagnostics where peptides can be used as a delivery vehicle for drugs or diagnostics. Moreover, lessons learned from nature in understanding peptide ligands are proving to be useful in designing better antibodies and small molecule therapeutics.
Keywords: c-MET, HMPs, heterodimer, peptide, VEGFR-2, antibody, small molecule, targeted drugs
Current Pharmaceutical Design
Title: Designer Peptides: Learning from Nature
Volume: 15 Issue: 6
Author(s): A. Shrivastava, A. D. Nunn and M. F. Tweedle
Affiliation:
Keywords: c-MET, HMPs, heterodimer, peptide, VEGFR-2, antibody, small molecule, targeted drugs
Abstract: Recent advances in designing peptide ligands for therapeutic targets are making peptides an attractive alternative to small molecules and proteins. It is now common to see peptides developed with affinities comparable to antibodies and specificities much better than small molecules or antibodies. This is especially true in the case of tumor targeting cytotoxic drugs or targeted diagnostics where peptides can be used as a delivery vehicle for drugs or diagnostics. Moreover, lessons learned from nature in understanding peptide ligands are proving to be useful in designing better antibodies and small molecule therapeutics.
Export Options
About this article
Cite this article as:
Shrivastava A., Nunn D. A. and Tweedle F. M., Designer Peptides: Learning from Nature, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315620
DOI https://dx.doi.org/10.2174/138161209787315620 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Detection of Formation of Recombinant Human Keratinocyte Growth Factor Loaded Chitosan Nanoparticles Based on its Optical Properties
Current Nanoscience New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Current Cancer Therapy Reviews NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends
Current Topics in Medicinal Chemistry Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Current Drug Metabolism SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases
Current Pharmaceutical Design Targeting Heparan Sulfate Proteoglycans in Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery HSP90 Inhibitors: Multi-Targeted Antitumor Effects and Novel Combinatorial Therapeutic Approaches in Cancer Therapy
Current Medicinal Chemistry Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety
Current Medicinal Chemistry Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Indole Derivatives as Anticancer Agents for Breast Cancer Therapy: A Review
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets Histone Lysine-Specific Methyltransferases and Demethylases in Carcinogenesis: New Targets for Cancer Therapy and Prevention
Current Cancer Drug Targets HPV Pathway Profiling: HPV Related Cervical Dysplasia and Carcinoma Studies
Current Pharmaceutical Design Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety Regulators of Chemokine Receptor Activity as Promising Anticancer Therapeutics
Current Cancer Drug Targets The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity
Current Medicinal Chemistry Anti-Apoptotic Genes in the Survival of Monocytic Cells During Infection
Current Genomics